Eculizumab and SB12 population PK
A two-compartment population PK model representing eculizumab or SB12 disposition, body-weight effects, disease-specific central volume, concentration, and cumulative exposure.
- Therapeutic
- Eculizumab or SB12
- Target
- Complement C5
- Disease
- Paroxysmal nocturnal hemoglobinuria
Biological model
A two-compartment population PK model representing eculizumab or SB12 disposition, body-weight effects, disease-specific central volume, concentration, and cumulative exposure.
Intervention
Eculizumab or SB12
Biological focus
Complement C5
Context
Paroxysmal nocturnal hemoglobinuria
Model details
A two-compartment population PK model representing eculizumab or SB12 disposition, body-weight effects, disease-specific central volume, concentration, and cumulative exposure.
Modeled states
- auc ug h mlug*h/mL
Modeled dynamic state for auc ug h ml.
- central mgmg
Modeled dynamic state for central mg.
- elapsed hh
Modeled dynamic state for elapsed h.
- peripheral mgmg
Modeled dynamic state for peripheral mg.
Key readouts
- Central eculizumab or SB12 concentrationunknown
Model-derived readout for central eculizumab or sb12 concentration.
- Peripheral concentrationunknown
Model-derived readout for peripheral concentration.
- Cumulative exposureug*h/mL
Model-derived readout for cumulative exposure.
- Individual clearanceunknown
Model-derived readout for individual clearance.
- body weight kgunknown
Model-derived readout for body weight kg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Healthy 300 mg IV single-dose PK/PD
How do body weight and disease context change eculizumab or SB12 concentration and exposure? Explore this intervention regimen through Central eculizumab or SB12 concentration, Peripheral concentration, Cumulative exposure, Individual clearance. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do body weight and disease context change eculizumab or SB12 concentration and exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do body weight and disease context change eculizumab or SB12 concentration and exposure?
pk cl l h
Model parameter controlling pk cl l h.
Exploratory range around the default value.
5 evenly spaced values in L/h. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumabEuropean Journal of Clinical Pharmacology
